Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05814757 · ClinicalTrials.gov registry record · Phase 2
OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)
A Phase 2 study, sponsored by Ocular Therapeutix.
- Completed
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT05814757: Completed Phase 2 study, sponsored by Ocular Therapeutix.
NCT05814757 is a Phase 2 study that has completed, run by Ocular Therapeutix. The registered enrollment target is 100 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05814757, a Phase 2 study, has completed, sponsored by Ocular Therapeutix.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED
Primary Outcome
Visual Analogue Scale (0 mm - no discomfort to 100mm - maximal (the most) discomfort)
Interventions
- DRUG OTX-DED
- DRUG Controlled Insertion
- DRUG Collagen Punctal Plug
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-05-11 |
| Est. Completion | 2024-05-22 |
| Phase | Phase 2 |
What the finished NCT05814757 record still lists
NCT05814757 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (25% lower).
The record links to 0 conditions, and to 3 interventions - of which OTX-DED is the first listed.
NCT05814757 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05814757 about?
NCT05814757 is a clinical study titled "OTX-DED for the Short-term Treatment of the Symptoms of Dry Eye Disease (DED)". To assess the efficacy and safety of OTX-DED for the short-term treatment of the symptoms of DED
What is the current status of trial NCT05814757?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-05-11. Estimated completion is 2024-05-22.
What interventions are being tested in trial NCT05814757?
The interventions under investigation include: OTX-DED (DRUG), Controlled Insertion (DRUG), Collagen Punctal Plug (DRUG).
Who is sponsoring clinical trial NCT05814757?
This trial is sponsored by Ocular Therapeutix, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05814757's enrollment target sits among peer trials
100 672nd of 2000 higher than 1,263 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI